Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot

24 de septiembre de 2026 actualizado por: Magnetic Tides

kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery

kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.

Descripción general del estudio

Descripción detallada

The goal of this pilot clinical trial is to assess the feasibility and preliminary efficacy of kTMP on upper limb motor recovery in chronic stroke compared to sham. We will conduct a 6-week double-blind, randomized, sham-controlled pilot study to test the beneficial influence of kTMP combined with simple motor tasks on kinematic outcomes such as range of motion of the upper arm, hand and fingers.

After baseline assessments, participants will be randomly allocated to either the kTMP group or the Control group. Participants, experimentalists, and outcome assessors will be blinded to group allocation. kTMP will begin within 1 week following randomization and will be delivered three times a week for 6 weeks. The primary endpoint will be assessed at the end of treatment, with follow-up assessments occurring 1 month, 3 months and 6 months following treatment completion. There is one assessment 4 weeks into the treatment phase to assess if patients continue to improve from 4 to 6 weeks of treatment.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

6

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • California
      • San Francisco, California, Estados Unidos, 94158
        • Reclutamiento
        • UCSF Mission Bay- Sandler Neurosciences Center
        • Contacto:
        • Investigador principal:
          • Ludovica Labruna, PhD
        • Investigador principal:
          • Richard Ivry, PhD
        • Investigador principal:
          • Karunesh Ganguly, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

  1. Adults aged 18-80 years who have a history of an ischemic or hemorrhagic stroke ≥ 12 m prior to enrollment.
  2. Fugl-Meyer Assessment: Upper Extremity (FMA UE) score 20-50.
  3. Ability to communicate, understand, and give appropriate consent. Participants can follow two-step commands.
  4. Motor evoked potentials in a hand muscle when stimulating ipsilesional cortex with suprathreshold single-pulse TMS (MEP positive).

Exclusion criteria:

  1. Participants with moderate or severe cognitive impairment (MMSE < 18).
  2. Participants with sensory deficits FMA-S < 6/12 (with proprioception < 4/8).
  3. Participants with severe apraxia (TULIA < 5).
  4. Language impairment or behavioral disorder that interferes with their ability to adhere to the protocol or to provide informed consent.
  5. Individuals who have a serious uncontrolled medical condition, including but not limited to severe cardiovascular and cardiopulmonary disease.
  6. Pregnancy or plans to become pregnant during the study period.
  7. Botulinum toxin injections of the affected upper extremity within 3 months prior to onset of study.
  8. Severe spasticity of the affected upper limb (Modified Ashworth ≥ 4).
  9. Absolute contraindications related to non-invasive brain stimulation, including:

9a) History of seizures in the last 12 months while taking anti-epilepsy medication 9b) Presence of any metal implants in the head (excluding the mouth), such as cortical stimulators and DBS, clips, coils, shunts, stents or skull plates, cochlear implants 9c) Permanent eye liner or head tattoos 9d) Implanted electronics such as pacemakers, defibrillators, intrathecal baclofen pumps or vagus nerve stimulator 9e) History of experiencing a serious adverse event during a previous transcranial magnetic stimulation (TMS) session

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Active kTMP

Participants received 8 V/m of active stimulation

A new non-invasive brain stimulation tool

Comparador falso: Sham kTMP

Participants receive sham stimulation (0.0 V/m electric field)

A new non-invasive brain stimulation tool with sham setting selected

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Movement Quality Index (MQI)
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

Kinematic data will be captured using a markerless, three-camera motion tracking system during a standardized reach-to-grasp task, with 30 trials per assessment. The cameras will reconstruct 3D hand, arm, and shoulder motion.

The primary outcome is change from baseline in the Movement Quality Index (MQI), compared between kTMP and sham groups. MQI is a composite kinematic score calculated as range of motion (ROM) divided by trial-to-trial variability (T2TV), both derived from the 3D reconstructions:

ROM: range, speed, and smoothness of hand/arm motion, including elbow and shoulder joint angles. T2TV: consistency across trials, measured as variance of 3D trajectories around the mean trajectory.

Enrollment, then weeks 4, 6, 10, 18, 30

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Fugl- Meyer Assessment (Upper Extremity) FMA-UE
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

The Fugl-Meyer Assessment (FMA) is a structured evaluation used to measure motor recovery after a stroke, with a total score range of 0-226. Higher scores indicate better motor function, while lower scores reflect greater impairment.

Enrollment, then weeks 4, 6, 10, 18, 30
Modified Ashworth Scale (MAS)
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

Test of resistance to passive movement about a joint, scores range from 0 to 5 where 0=no increase in muscle tone and 5=affected part(s) rigid. Hight scores indicate greater muscle tone.

Enrollment, then weeks 4, 6, 10, 18, 30
Stroke Impact Scale (SIS)
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

Self reported questionnaire that evaluates disability and health related quality of life after stroke, consisting of 59 items, assessing strength, hand function, ADL/iADL, mobility, communication, emotion, memory and thinking, participation/role function. Each item is rated in a 5 point Likert scale, where 1 equals could not do it at all and 5 equals not difficult at all. Score ranges 0-100. Higher score indicates less disability and high quality of life after stroke.

Enrollment, then weeks 4, 6, 10, 18, 30
EuroQOL (EQ-5D)
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

A health questionnaire that measures 5 dimensions including mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each item is described by 3 levels of problems, where 1=none, 2=mild to moderate, and 3=severe. This provides a simple single index value for health status, where a higher score indicates worse health state.

Enrollment, then weeks 4, 6, 10, 18, 30
Motor Activity Log (MAL)
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

Self reported perception of Quality of movement are rated in 30 functional tasks, scored on a 6 point ordinal scale where 0=weaker arm not used at all for that activity and 5=ability to use the weaker arm for that activity is as good as before the stroke(normal). A higher score indicates better quality upper extremity movement.

Enrollment, then weeks 4, 6, 10, 18, 30
Wolf Motor Function Test (WMFT)
Periodo de tiempo: Enrollment, then weeks 4, 6, 10, 18, 30

A quantitative measure of upper extremity motor abilitythrough timed and functional tasks will be administered by a trained experimenter.

Enrollment, then weeks 4, 6, 10, 18, 30
Stroke Specific QOL (SSQOL)
Periodo de tiempo: At enrollment, then weeks 4, 6, 10, 18, and 30

Questionnaire consisting of 49 items in the 12 domains of mobility, energy, upper extremity function, work and productivity, mood, self-care, social roles, family roles, vision, language, thinking and personality. Each item is assessed on a 5 point Guttman type scale, where 1=total help; couldn't do it at all; strongly agree and 5 =no help needed; no trouble at all; strongly disagree. Higher scores indicate better functioning.

At enrollment, then weeks 4, 6, 10, 18, and 30

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

28 de febrero de 2027

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

1 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

1 de junio de 2026

Publicado por primera vez (Actual)

5 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir